News Daily News CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition Michael O'Riordan August 04, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017